Amentadione from the alga "cystoseira usneoides" as a novel osteoarthritis protective agent in an ex vivo co-culture OA model by Araújo, Nuna et al.
marine drugs 
Article
Amentadione from the Alga Cystoseira usneoides
as a Novel Osteoarthritis Protective Agent
in an Ex Vivo Co-Culture OA Model
Nuna Araújo 1, Carla S. B. Viegas 1,2, Eva Zubía 3, Joana Magalhães 4,5,6 , Acácio Ramos 7,
Maria M. Carvalho 7, Henrique Cruz 7, João Paulo Sousa 7, Francisco J. Blanco 4,5 ,
Cees Vermeer 8 and Dina C. Simes 1,2,*
1 Centre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal; naraujo@ualg.pt (N.A.);
caviegas@ualg.pt (C.S.B.V.)
2 GenoGla Diagnostics, Centre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal
3 Department of Organic Chemistry, Faculty of Marine and Environmental Sciences, University of Cadiz,
11510 Puerto Real (Cádiz), Spain; eva.zubia@uca.es
4 Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación
Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas,
15006 A Coruña, Spain; joana.cristina.silva.magalhaes@sergas.es (J.M.); fblagar@sergas.es (F.J.B.)
5 Agrupación Estratégica CICA-INIBIC, Universidade da Coruña (UDC), 15006 A Coruña, Spain
6 Centro de Investigación Biomédica en Red (CIBER), 28029 Madrid, Spain
7 Department of Orthopedics and Traumatology, Hospital Particular do Algarve (HPA),
8005-226 Gambelas-Faro, Portugal; acacioramos@gmail.com (A.R.); mariamiguelfc@gmail.com (M.M.C.);
cruzhenrique@hotmail.com (H.C.); jprsous@gmail.com (J.P.S.)
8 Cardiovascular Research Institute CARIM, Maastricht University, 6229 EV Maastricht, The Netherlands;
cees.vermeer@outlook.com
* Correspondence: dsimes@ualg.pt
Received: 12 November 2020; Accepted: 3 December 2020; Published: 7 December 2020


Abstract: Osteoarthritis (OA) remains a prevalent chronic disease without effective prevention and
treatment. Amentadione (YP), a meroditerpenoid purified from the alga Cystoseira usneoides, has
demonstrated anti-inflammatory activity. Here, we investigated the YP anti-osteoarthritic potential, by
using a novel OA preclinical drug development pipeline designed to evaluate the anti-inflammatory
and anti-mineralizing activities of potential OA-protective compounds. The workflow was based on
in vitro primary cell cultures followed by human cartilage explants assays and a new OA co-culture
model, combining cartilage explants with synoviocytes under interleukin-1β (IL-1β) or hydroxyapatite
(HAP) stimulation. A combination of gene expression analysis and measurement of inflammatory
mediators showed that the proposed model mimicked early disease stages, while YP counteracted
inflammatory responses by downregulation of COX-2 and IL-6, improved cartilage homeostasis by
downregulation of MMP3 and the chondrocytes hypertrophic differentiation factors Col10 and Runx2.
Importantly, YP downregulated NF-κB gene expression and decreased phosphorylated IkBα/total
IkBα ratio in chondrocytes. These results indicate the co-culture as a relevant pre-clinical OA model,
and strongly suggest YP as a cartilage protective factor by inhibiting inflammatory, mineralizing,
catabolic and differentiation processes during OA development, through inhibition of NF-κB signaling
pathways, with high therapeutic potential.
Keywords: osteoarthritis; amentadione; preclinical osteoarthritis models; marine compounds;
Cystoseira usneoides; inflammation; mineralization; chondrocytes; synoviocytes; cartilage explants
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1. Introduction
Osteoarthritis (OA) is a prevalent degenerative arthritic disease, a chronic condition that causes
pain and disability among elderly patients [1,2]. An estimated 10% to 15% of all adults aged over
60 have some degree of OA [3], with prevalence doubling since the mid-20th century [4]. OA has
been defined as a “whole joint” and multifactorial disease, characterized by synovial inflammation,
progressive loss of articular cartilage and remodeling of the underlying bone [5,6].
Although OA physiopathology is still not completely understood, chronic inflammation is known
to play a critical role in disease development and progression, with accumulating evidence supporting
the association between OA pathology and different markers of inflammation [7]. OA cartilage and
synovium overexpress cytokines and pro-inflammatory mediators that stimulate the accumulation
of proteolytic enzymes, aggrecanases and matrix metalloproteinases (MMPs) responsible for the
extracellular matrix (ECM) degradation, and for mediating detrimental effects through innate immunity
signals [8,9]. In particular, MMP3 is known to mediate the integrity of various constituents of the ECM,
such as collagens (types II, III, IV, V, VII, IX, X), fibronectin, elastin, proteoglycans, directly or through
the activation of other pro-MMPs and pro-TNFα, in OA [10]. This molecular condition together with
chondrocyte differentiation into a hypertrophic phenotype, result in loss of the ability to restore the
ECM with consequent cartilage degradation. Basic calcium phosphate (BCP) deposition in the cartilage
and synovial membrane is closely associated with OA inflammation, and contributes to local tissue
damage and failed tissue repair, further intensifying hyaline articular cartilage loss and progressive
joint deterioration [11–13].
Current osteoarthritis prevention and treatment are still very limited and unsatisfactory, with
therapeutics focused mainly in drugs which improve pain or symptoms, such as topic and oral
nonsteroidal anti-inflammatory drugs, acetaminophen, and opioids [14]. Although there are some
advances in the design of new molecules to target cartilage repair and bone, or to treat inflammation
and pain, at present, no effective OA drugs have yet been approved [15], making the search for new
potential molecules a priority to overcome the growing burden of OA.
In addition, the lack of reliable models able to simulate the physiologic OA scenario, contributes
to slow down the discovery of novel preventive or therapeutic agents. Monolayer (2D) cell culture
approaches are limited by the lack of a physiologic context, while three-dimensional human tissue
systems, although taking into consideration cell–cell and cell–extracellular matrix interactions, are
still not demonstrative of the OA heterogeneity [16,17]. Preclinical animal models represent a more
complex system, but are not totally representative of the human physiopathology, frequently leading
to the failure of therapeutic responses in a later stage of the drug validation process.
In the search of effective drugs that might prevent or slow down the development of the disease,
natural products derived from plants and marine organisms, remain a source of new molecular
entities for the treatment of chronic inflammatory related diseases, including osteoarthritis [18,19].
Dietary supplements, of natural and synthetic origin, representing a nutritional and health benefit,
were already associated with OA in human clinical trials. Although most were associated with OA
pain relief, some were shown to modify the inflammatory OA process, by balancing anabolic and
catabolic joint events, and promoting the synthesis of structural articulation precursors [20–22].
Among natural products, those containing phenolic rings, such as the flavonoids and some
meroterpenoids, are usually provided of interesting biological activities, and have been shown to
modulate cytokines such as tumor necrosis factor-α (TNFα), interleukin-1β (IL-1β) and interleukin-6
(IL-6), with a crucial role in chronic inflammatory and autoimmune diseases [23]. Some terpenoids
based drugs are already available in the pharmaceutical market such as artemisinin and paclitaxel
(Taxol®), acting as antimalarial and anticancer drugs, respectively [24].
In recent years, a series of meroterpenoids isolated from the brown alga Cystoseira usneoides
have been shown to exhibit anti-inflammatory and antioxidant activities, by reducing the secretion
of pro-inflammatory cytokines and downregulating the expressions of COX-2 and iNOS enzymes
in THP-1 activated macrophages [25–28]. Among those, amentadione (YP) (Figure S1) showed
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radical-scavenging activity and demonstrated a significant role in reducing the production of TNFα
in LPS-stimulated THP-1 human macrophages [26]. These results led us to further investigate the
anti-inflammatory action of this pure marine compound and its potential as a novel cartilage protective
agent in an OA context. For this purpose, we designed an OA preclinical pipeline consisting of
an in vitro 2D-cell based system followed by an ex vivo explant-based and co-culture OA models.
Our aim is to evaluate the potential protective effect of YP in the interplay between mineralization and
inflammatory processes involved in OA development and progression.
2. Results
2.1. YP Acts as an Anti-Inflammatory Agent in the Articular OA Cell System Model
To evaluate the anti-inflammatory potential of YP in the mineralization and inflammatory processes
involved in OA development and progression, a first screening was performed on THP-1 macrophages
(THP-1 MOM). The inflammatory response of lipopolysaccharide (LPS)-induced THP-1 MOM was
significantly reduced by pre-treatment with YP in a dose dependent manner (Figure S2a), as previously
reported [25,26]. Additionally, the increased levels of TNFα production in calcium/phosphate
(Ca/P) hydroxyapatite (HAP)-treated THP-1 MOM, confirmed the induction of a pro-inflammatory
response [29], which was reduced by YP pre-treatment (Figure S2b). Cell proliferation assays were
performed to confirm that tested HAP and YP did not affect THP-1 MOM cell viability (Figure S3).
Based on these results, YP was further tested on a previously established articular OA cell system,
consisting of human chondrocytes and synoviocytes primary cell cultures [30].
Human synoviocytes and chondrocytes primary cells were pre-treated with YP for 24 h followed
by IL-1β (Figure 1) and HAP (Figure 2) stimulation. The effect of YP was determined by measuring
gene expression of the inflammatory marker cyclo-oxygenase-2 (COX-2) and levels of IL-6 released into
the cell culture media. Pre-treatment with YP followed by IL-1β stimulation resulted in a significant
downregulation of COX-2 and decreased levels of IL-6 in both type of cells, relative to non-treated
cells (Figure 1a,b). No cytotoxicity was observed in chondrocytes and synoviocytes, when treated with
different YP concentrations (Figure S4).
Figure 1. Amentadione (YP) reduces the levels of inflammatory markers in articular-derived cells
stimulated with IL-1β (a,b). Primary chondrocytes and synoviocytes were pre-treated with 10 µM YP
for 24 h, followed by stimulation with 10 ng/mL IL-1β during different time points. (a) Relative gene
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expression of the inflammatory marker COX-2 was determined by qPCR, at 3 h and 6h post IL-1β
stimulation in chondrocytes and synoviocytes. (b) Levels of IL-6 in cell culture media 6 h post IL-1β
stimulation, determined by ELISA. Cells treated with 2 µM dexamethasone (DXM) were used as
a positive anti-inflammatory control. Data are presented as means of at least three independent
experiments. All graphs show mean ± SD. One-way ANOVA and multiple comparisons were
achieved with the Dunnett’s test. Statistical significance was defined as p ≤ 0.05 (*), p ≤ 0.005 (**) and
p ≤ 0.0005 (***).
Figure 2. YP downregulates the inflammatory marker COX-2 in articular-derived cells stimulated
with hydroxyapatite (HAP). Primary chondrocytes and synoviocytes were pre-treated with 10 µM
YP for 24 h, followed by stimulation with 750 µg/mL HAP during 6 h. Relative gene expression of
COX-2 was determined by qPCR, at 6 h post HAP stimulation in chondrocytes and synoviocytes.
Data are presented as means of two independent experiments, with duplicates. All graphs show mean
± SD. One-way ANOVA and multiple comparisons were achieved with the Dunnett’s test. Statistical
significance was defined as p ≤ 0.05 (*) and p ≤ 0.005 (**).
Interestingly, a similar upregulation of the inflammatory marker COX-2 was observed in
chondrocytes and synoviocytes treated with HAP, which was reduced by YP pre-treatment (Figure 2).
No cytotoxicity was observed in chondrocytes and synoviocytes, when treated with different HAP
concentrations (Figure S5).
These results demonstrate a promising anti-inflammatory effect of YP in the articular OA cell
system model, through downregulation of inflammatory genes either when stimulated with IL-1β or
treated with the mineralizing agent HAP.
2.2. YP Modulates Cartilage Homeostasis under Mineralizing Conditions in an Ex-Vivo Cartilage
Explant Model
Since cartilage is the main affected tissue in OA, and ectopic mineralization is a known trigger of
several joint alterations, including inflammation and cell differentiation, ultimately leading to cartilage
degradation, cartilage tissue explants were first selected as an experimental model to evaluate ex
vivo the effect of YP in response to HAP stimulation. Cartilage explants used in all experimental
conditions were classified as normal- to early-OA tissues through the modified Mankin score [31].
Histological analysis revealed a smooth surface, a normal and uniform structural organization, and a
normal to slight reduction in matrix staining, with Mankin total score ranging from 1 to 4 in the 1/13
modified Mankin scale (Table S1). The results showed that HAP treatment significantly upregulated
collagen-10 (Col10), runt-related transcription factor-2 (Runx2) and matrix metalloproteinase-3 (MMP3)
relative to control explants (Figure 3a), with simultaneous increased accumulation of MMP3 and the
inflammatory marker IL-6 (Figure 3b). Pre-treatment of human cartilage explants with YP and further
HAP stimulation, resulted not only in a significant down-regulation of the referred differentiation and
ECM-related genes (Figure 3a), but also in decreased levels of the inflammatory marker IL-6 and the
catabolic OA marker MMP3, responsible for ECM degradation (Figure 3b).
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Figure 3. YP downregulates cell differentiation, extracellular matrix degradation and pro-inflammatory
markers associated with osteoarthritis (OA) in the ex vivo cartilage explant model under HAP
stimulation. Human cartilage explants were pre-treated with 10 µM YP for 24 h, followed by 72 h of
750 µg/mL HAP stimulation. Relative gene expression of Col10, Runx2 and MMP3 was determined by
qPCR (a), and levels of MMP3 and IL-6 accumulation in the culture media were determined by ELISA
(b). DXM indicates treatments with 2 µM dexamethasone. Data are presented as means of at least three
independent experiments. All graphs show mean ±SD. One-way ANOVA and multiple comparisons
were achieved with the Dunnett’s test. Statistical significance was defined as p ≤ 0.05 (*), p ≤ 0.005 (**)
and p ≤ 0.0005 (***).
2.3. YP Function as a Protective Agent against Cartilage Deterioration under OA Promoting Conditions
in an Explant-Based Co-Culture OA Model
Since in the joint environment cartilage and synovial membrane are known to be involved in an
interrelated and complex crosstalk affecting cartilage integrity and driving OA progression, an ex vivo
explant-based co-culture OA model was developed and used to study the effects of YP in cartilage.
Human cartilage explants were co-cultured with primary human synoviocytes and treated with IL-1β
(Figure 4) and HAP (Figure 5) to simulate inflammatory and mineralizing conditions. Increased gene
expression of COX-2, IL-6 and MMP3 in the co-culture cartilage explants treated with IL-1β, clearly
indicated an induction of inflammatory reactions and ECM degradation at cartilage tissue level, which
were consistently diminished in cartilage pre-treated with YP (Figure 4).
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Figure 4. YP downregulates pro-inflammatory and ECM degradation markers associated with OA
in the explant-based co-culture OA model under inflammatory stimulation with IL-1β. Cartilage
explants co-cultured with human primary synoviocytes were pre-treated with 10 µM YP for 24 h,
followed by 24 h of 10 ng/mL IL-1β stimulation. Relative gene expression of COX-2, IL-6 and MMP3 in
cartilage explants were determined by qPCR. DXM indicates treatments with 2 µM dexamethasone.
Data are presented as means of at least three independent experiments. One-way ANOVA and multiple
comparisons were achieved with the Dunnett’s test. All graphs show mean ±SD. Statistical significance
was defined as p ≤ 0.005 (**) and p ≤ 0.0005 (***).
Figure 5. YP decreases the production of ECM degradation and pro-inflammatory markers in the
explant-based co-culture OA model under mineralizing conditions. Cartilage explants co-cultured
with human primary synoviocytes were pre-treated with 10 µM YP 24 h, followed by 72 h of 750 µg/mL
HAP stimulation. Levels of MMP3 and IL-6 accumulation in the co-culture media were determined
by ELISA. DXM indicates treatments with 2 µM dexamethasone. Data are presented as means of at
least three independent experiments. One-way ANOVA and multiple comparisons were achieved
with the Dunnett’s test. All graphs show mean ±SD. Statistical significance was defined as p ≤ 0.05 (*),
p ≤ 0.005 (**) and p ≤ 0.0005 (***).
Additionally, increased levels of MMP3 and IL-6 in the cell culture media of co-culture cartilage
explants treated with HAP demonstrated the interplay between mineralization and inflammation with
consequent increased levels of inflammatory and ECM degrading markers, which were decreased with
the YP pre-treatment (Figure 5).
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Overall, considering the effects of YP at cartilage tissue level, evaluated using the cartilage explants
and the explant-based co-culture models, the results suggest that YP exerts a cartilage protective effect,
by reducing inflammatory reactions and preventing chondrocyte differentiation towards extracellular
matrix mineralization and degradation.
2.4. YP Downregulates NF-kB Expression and Inhibits Ikbα Phosphorylation in Primary Chondrocyte Cells
Since YP was able to downregulate several pro-inflammatory mediators known to be directly
regulated by the nuclear factor-κB (NF-kB) signaling pathway, we investigated whether the
anti-inflammatory action of YP was due to its effect on NF-kB transcription and phosphorylation of its
inhibitor IkBα.
In human primary articular chondrocytes, pre-treated with YP for 24 h followed by IL-1β
stimulation, NF-kB expression was significantly downregulated at all-time points tested (Figure 6a).
To determine the effect of YP in IkBα phosphorylation (pIkBα), known to precede NF-kB nuclear
translocation, an initial experiment was performed to determine the optimal time point of pIkBα under
IL-1β stimulation. Western blot analysis of chondrocyte protein extracts indicated increased levels
of pIkBα from 30 min to 60 min of IL-1β treatment (Figure S6). Based on that, detection of pIkBα in
chondrocytes pre-treated with YP for 24 h followed by 30 min IL-1β stimulation suggests a reduction of
pIkBα in the YP treated chondrocytes relatively to the untreated and IL-1β stimulated cells (Figure 6b).
Specific ELISA assays measuring pIkBα and total IkBα at 30 min shown that YP treatment reduces the
ratio of pIkBα/total IkBα (Figure 6c), strongly indicating an effect of YP on IkBα phosphorylation.
Figure 6. YP downregulates NF-kB expression and inhibits IkBα phosphorylation in IL-1β-stimulated
primary articular chondrocytes. (a) Relative gene expression of NF-kB was determined by qPCR at 3 h
and 6 h post 10 ng/mL IL-1β stimulation. Data is presented as mean of three independent experiments.
(b) Total protein extracts of chondrocytes cultured in untreated conditions, stimulated with 10 ng/mL
IL-1β for 30 min, and pre-treated with YP (µM) followed by 30 min of 10 ng/mL IL-1β treatment,
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were analyzed by Western blot to detect pIkBα. Position of relevant molecular mass marker (kDa) is
indicated on the right side and GAPDH was used as loading control. (c) The pIkBα ratio (pIkBα/total
IkBα) was determined in total protein extracts of chondrocytes cultured in control conditions (Ctr);
30 min of IL-1β (10 ng/mL) treatment; and pre-treated with YP for 24 h followed by 30 min of IL-1β
stimulation (YP), by measuring the content of total and pIkBα with the specific InstantOne ELISA assay
kit. Data is presented as mean of two out of four representative experiments. All graphs show mean
±SD. One-way ANOVA and multiple comparisons were achieved with the Dunnett’s test. Statistical
significance was defined as p ≤ 0.05 (*), p ≤ 0.005 (**) and p ≤ 0.0005 (***).
These results demonstrate an anti-inflammatory effect of YP in articular chondrocytes,
by downregulation of NF-kB expression, and inhibition of its activation through modulation of
IkBα phosphorylation, and consequent downregulation of several NF-kB-related target genes.
3. Discussion
In this study we demonstrated that YP, a meroterpenoid isolated from the brown alga C.
usneoides [26], is able to decrease inflammation, cell differentiation and extracellular matrix (ECM)
degradation in different osteoarthritis in vitro/ex vivo OA model systems. By using a pipeline with
increasing complexity, from 2D monolayer cultures of THP-1 macrophages, primary chondrocytes
and synoviocytes, to ex vivo culture of human cartilage explants and a newly developed OA
explant-based co-culture model, YP consistently promoted a protective effect under pro-inflammatory
and mineralizing stimuli. These results bring new evidences on the health benefits of YP as a protective
OA agent by attenuating cartilage degrading processes under known OA promoting stimuli, with
consequent cartilage maintenance promoting effects, with potential therapeutic application.
In OA, cartilage loss and synovial membrane inflammation are two major factors responsible
for disease progression and associated outcomes. Complex and interconnected molecular events of
cartilage homeostasis disruption associated to inflammation known to fuel cartilage degradation, are
recognized as crucial for disease development and important targets for therapeutic approaches [32].
Cartilage degradation is associated with chondrocytes differentiation leading to apoptosis and
deposition of a mineralized extracellular matrix, which in turn contributes to loss of ECM integrity and
inflammation [33]. In fact, although the pathways involved in the crosstalk between inflammation and
cartilage degradation are still not completely clarified, mineralizing and inflammatory events occur in
a close related manner during OA progression [30]. BCP and calcium pyrophosphate (CPP) crystals,
consistently associate with the early stage of OA and have a pathogenic role in the development
and rapid progression to end-stage OA [11,12]. BCPs have been found in the synovial fluid and
membrane, and cartilage from OA patients [34], and associated with the activation of macrophages,
synovial fibroblasts and articular cells, resulting in increased cell proliferation and production of
pro-inflammatory cytokines and MMPs [35,36]. In concordance, our results show an inflammatory
response to hydroxyapatite stimulation in all tested OA models, similar to those obtained with the
classical inflammatory cytokine IL-1β, and to previously reported effects in OA cell models [30,37].
Of particular relevance, at cartilage level, treatment with hydroxyapatite induced overexpression
of Col10 and Runx2, indicative of triggered chondrocyte differentiation towards hypertrophy and
calcification. In addition, up-regulation of COX-2 and IL-6, widely known to be associated with
joint inflammation, and MMP3, a major responsible for ECM degradation, clearly demonstrate
the detrimental potential of calcification in OA. This is in line with recent data showing that BCP
upregulate IL-6 in in vivo murine OA models, which in turn induced the expression of genes involved
in calcification, promoting BCP formation and potentiating a vicious cycle [38]. Increased levels of BCP
and IL-6 were also associated with cartilage degradation through the induction of matrix-degrading
enzymes activity in chondrocytes [38]. In another study, calcium-phosphate complexes were shown to
induce MMP3 and MMP13, which in turn, promoted the release of calcium and phosphate through
degradation of the ECM calcified cartilage, in a positive loop [39]. Additionally, the effect of IL-1β
on cartilage is known to reflect not only the catabolic effect of aggrecanases and MMPs upregulation,
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but also the downregulation of chondrogenic extracellular matrix synthesis [40,41]. In concordance,
our results showed that IL-1β induced an overexpression of MMP3. Overall, our results clearly
demonstrated the potentialities of the developed ex vivo explant-based co-culture OA model to study
the interplay between cartilage degradation and inflammation, reflecting early molecular events
leading to subsequent phenotypic cartilage alterations, of critical value in drug development for
potential anti-osteoarthritic compounds such as YP.
YP has previously shown to have anti-inflammatory properties associated with the inhibition
of TNFα in LPS-activated human macrophages [26]. In the present study, we demonstrated that YP
was able to counteract inflammation, cell differentiation and ECM degradation, induced not only
by IL-1β but also by hydroxyapatite, in all OA models, including primary articular cells, cartilage
explants and ex vivo explant-based co-culture systems. These effects were demonstrated at multiple
levels. Through downregulation of master players involved in pro-inflammatory reactions, such as
NF-kB, COX-2 and IL-6, and the ECM catabolic marker MMP3, YP is directly contributing to preserve
cartilage homeostasis, by avoiding ECM disruption and cartilage collapse. Similarly, the capacity to
downregulate crucial genes involved in chondrocyte differentiation such as Col10 and Runx2, suggests
YP as an inhibitor of chondrocytes hypertrophic differentiation. The resulting decrease of apoptosis
and ECM mineralization, indirectly contributes to a consequent decrease of pro-inflammatory reactions,
ultimately preserving cartilage homeostasis. Although our studies were not directed to evaluate the
effect of YP as a structural cartilage-modifying drug, its capacity to inhibit early molecular events
leading to joint deterioration, suggests YP as a potential disease modifying OA drug, worth to be
further investigated.
Additionally, this YP protective role might represent a promising alternative to the
anti-inflammatory drugs commercially available to manage symptomatology associated with OA and
chronic autoimmune and inflammatory diseases, mostly based on NSAIDs target to inactivate COX
enzymes (COX-1 and COX-2) [42], or biologics targeting crucial pro-inflammatory cytokines such
as TNFα and IL-1β [43,44]. Although some effectiveness has been shown in slowing inflammatory
reactions, the growing list of adverse side effects and the high percentage of patients presenting
no response to these treatments, clearly demonstrate the urgent need for safer and more effective
anti-inflammatory drugs. In this field, natural derived products, such as YP, have been considered as
promising and valid alternatives. Some examples are the tetracyclic triterpenoid glycoside Ginsenoside
Rb1 (G-Rb1) and curcumin, which have shown both in vitro and in vivo the capacity of targeting the
production of several pro-inflammatory species and promoting the synthesis of anti-inflammatory
mediators, with cartilage protective effects [45–48].
Considering the pivotal role of NF-kB as a major regulator of inflammation, many strategies
have been developed to block NF-kB signaling in a variety of inflammatory disease settings [49].
Although in the context of OA these strategies are still in their infancy, the crucial role of NF-kB
signaling mediating inflammatory responses, but also the hypertrophic conversion of articular
cartilage chondrocytes, leading to ECM damage and cartilage destruction, is of paramount importance
in the disease context [50,51]. Our results demonstrate that YP is able to downregulate NF-kB
expression and decrease IkBα phosphorylation in chondrocytes, strongly suggesting that YP cartilage
protective properties are associated, at least in part, with the inhibition of NF-kB nuclear translocation
and consequent decreased activation of catabolic pathways, including expression of cytokines and
chemokines, inflammatory mediators, matrix degrading enzymes, and regulators of chondrocytes
differentiation. In agreement, YP treatments consistently decreased levels of COX-2 and IL-6, MMP3,
Col10 and Runx2 in cartilage tissue, clearly demonstrating the potential of YP in ameliorating cartilage
homeostasis and integrity, a good rationale for the exploitation of YP in the treatment of OA.
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4. Materials and Methods
4.1. Isolation of Amentadione (YP)
The meroditerpenoid amentadione (YP) was isolated from the brown alga Cystoseira usneoides
collected off the coast of Tarifa (Spain) as previously described [26]. Briefly, the frozen alga was extracted
with methanol and after evaporation of the solution under reduced pressure, the aqueous residue was
extracted with diethyl ether. The resulting extract was subjected to column chromatography (CC) on
silica gel (70–230 mesh) (Merck KGaA, Darmstadt, Germany) eluting with a mixture of n-hexane/diethyl
ether (50:50, v/v), then diethyl ether, mixtures of chloroform/methanol (90:10 and 80:20, v/v), and finally
methanol. The fraction that eluted with chloroform/methanol (90:10, v/v) was further separated by
CC on silica gel using as eluents mixtures of n-hexane/ethyl acetate (50:50 to 30:70, v/v), then ethyl
acetate, and finally methanol. The compound YP was obtained by reversed phase HPLC separation of
selected subfractions using as eluent methanol/water (70:30, v/v). HPLC separations were performed
on a LaChrom-Hitachi apparatus (Merck), equipped with Kromasil 100-5C18 columns (250 × 10 mm,
5 µm or 250 × 4.6 mm, 5 µm) (Hichrom, Reading, UK), using an RI-71 differential refractometer or
L-7400 UV detector (Merck). The pure compound YP was identified as amentadione [52] by NMR
and HRMS analysis (Figure S1) and the negative optical rotation. NMR spectra were recorded on an
Agilent 500 spectrometer (Agilent Technologies, Santa Clara, CA, USA), HRMS spectra were obtained
on a Waters SYNAPT G2 spectrometer (Waters, Milford, MA, USA), and optical rotation was measured
on a JASCO P-2000 polarimeter (JASCO, Tokyo, Japan).
4.2. Cell Culture
Primary human chondrocytes and synoviocytes were commercially acquired (chondrocytes,
Lonza, Visp, Switzerland; synoviocytes, ECACC, Sigma-Aldrich, St. Louis, MO, USA) and obtained
from human tissue explants using well-defined methodology [53,54]. Both cell types were cultured
in Advanced Dulbecco’s Modified Eagle’s Medium (Adv DMEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (v/v) of heat-inactivated Fetal Bovine Serum (FBS, Sigma-Aldrich), 1 mM of
l-glutamine (l-Gln, Invitrogen) and 1% (v/v) of penicillin-streptomycin (PS, Invitrogen). THP-1 cell
line was kindly given by Dr. Santos (CBME, University of Algarve, Faro) and was cultured according
to ATCC instructions in RPMI Growth Medium (RPMI 1640 with l-glutamine (Lonza)) containing 10%
heat-inactivated FBS (invitrogen) and 1% PS. Differentiation into THP-1 macrophage (THP-1 MOM)
cells was achieved by culturing THP-1 cells in 25 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma)
in complete RPMI for 48 h. All cell cultures were maintained at 37 ◦C in a humidified atmosphere
containing 5% CO2, and experiments were performed on confluent cells.
4.3. Inflammatory Assays in Monolayer Cells
THP-1 MOM (1 × 106 cells/mL) were cultured in 500 µL of complete RPMI supplemented with
different amentadione (YP) concentrations (2.5, 5 and 10 µM) in dose-dependence experiments and with
10µM YP in subsequent experiments, or with 2µM dexamethasone (DXM), during 24 h. After, 100 ng/mL
of lipopolysaccharides (LPS) or synthetic hydroxyapatite nano-crystals (HAP) (Sigma) (750 µg/mL)
were added to the culture media for another 24 h or 72 h, respectively. Confluent chondrocytes and
synoviocytes were cultured in 1 mL of Adv DMEM supplemented with 10 µM of YP or 2 µM of DXM
during 24 h, and further treated with: 10 ng/mL of interleukin-1β (IL-1β) for 3 and 6 h, or for 30 min
in the assay for pIKBα content analysis; 750 µg/mL HAP for 6h. Control cells were cultured with
respective media without any treatment. At determined time points, cell culture media were collected
for ELISA analysis and cells harvested for RNA extraction.
4.4. Cell Proliferation
THP-1 MOM cells seeded in 96-well plates at 2 × 105 cells/well, and confluent chondrocytes
and synoviocytes, were cultured in their respective growth media and supplemented with
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different concentrations of YP and HAP. Cell viability was determined at appropriate time
points using the CellTiter 96 cell proliferation assay (Promega, Madison, WI, USA), following
manufacturer’s instructions.
4.5. Cartilage Collection and Tissue Explants Preparation
Knee articular cartilage was obtained from osteoarticular cuts performed on the femoral and
tibial sides, from eight patients (4 male and 4 female, aged 71.5 ± 5.9 years) who had undergone
arthroplasty surgeries at Hospital Particular do Algarve (Faro, Portugal). This study was approved
by the ethics committee of the hospital, and written informed consent was obtained from all the
participants. All principles of the Declaration of Helsinki of 1975, as revised in 2000, were followed.
Macroscopically normal full-depth cartilage slices were removed in sterile conditions using a scalpel,
collected in complete Adv DMEM media, and incubated for 24 h, at 37 ◦C, in a humidified atmosphere
containing 5% CO2, for tissue equilibration before preparation of tissue explants. After equilibration,
2 mm diameter and 1.71 ± 0.70 mm thickness cartilage explants, were obtained using a 2 mm biopsy
punch (Integra-Miltex). Samples of the initial cartilage explant tissues were fixed in 4% PFA for
histological evaluation.
4.6. Cartilage Explants Assays
Cartilage explants (8–10 per well), were plated in a 12 well plate and cultured at 37 ◦C, in a
humidified atmosphere containing 5% CO2, in 1 mL of complete Adv DMEM media supplemented
with 10 µM of YP or 2 µM DXM for 24 h, and then treated with HAP (750 µg/mL), for further 72 h.
As controls, explants were cultured without treatment. At the end of each experiment, cartilage explants
were collected, washed twice with PBS, immediately processed for RNA extraction as described below,
and the cell culture media collected for ELISA assays.
4.7. Co-Culture Assays
Cartilage explants (10 per well), were plated in a 12 well plate and co-cultured with synoviocytes
in a transwell system (6.5 mm insert diameter, 3.0 µm polyester membrane, Corning Incorporated Life
Sciences), in 1.8 mL of complete Adv DMEM, at 37 ◦C, in a humidified atmosphere containing 5% CO2.
To evaluate the effect of YP, co-cultures were supplemented with 10 µM of YP or 2 µM DXM
for 24 h, followed by treatment with IL-1β (10 ng/mL) during 24 h, or HAP (750 µg/mL) during 72 h.
Cartilage explants were collected as described above for RNA extraction, and cell media collected for
ELISA analysis.
4.8. RNA Extraction, cDNA Amplification and Quantitative Real-Time PCR (qPCR)
Cartilage tissue was immediately snap-frozen and manually grounded to powder in liquid nitrogen.
Cells and tissue lysis was performed in a proportion of 1 mL of 4 M guanidine thiocyanate solution
per 107 cells or 100 mg cartilage tissue, thoroughly mixed and passed 10 times through a 22G needle.
Total RNA was further extracted as described by Chomczynski and Sacchi [55]. Briefly, homogenates
were sequentially mixed with 2 M sodium citrate pH 4, phenol pH 4.2 and chloroform/isoamyl alcohol.
After centrifugation, total RNA present in the aqueous phase was precipitated with isopropanol,
redissolved in 4 M guanidine thiocyanate solution, reprecipitated in isopropanol, washed with 75%
ethanol and resuspended in Sigma water. RNA concentration was determined by spectrophotometry
at 260 nm (Nanodrop 1000, Thermo Scientific, Waltham, MA, USA). RNA was then treated with
RQ1 RNase-free DNase (Promega, Madison, WI, USA) and reverse-transcribed using the qScipt
cDNA SuperMix (Quanta bio, Beverly, MA, USA) according to manufacturer’s recommendations.
Quantitative real-time PCR reactions were performed using the CFX connect, Real time System
(Bio-Rad, Richmond, CA, USA), SoFast Eva Green Supermix (Bio-Rad, Richmond, CA, USA), 300 nM
of forward and reverse gene-specific primers for genes of interest (Table S2), and a 1:5 cDNA dilution.
The following PCR conditions were used: initial denaturation/enzyme activation step at 95 ◦C for
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13 min, 50 cycles of amplification (one cycle is 15 s at 95 ◦C and 30 s at 68 ◦C). Fluorescence was
measured at the end of each extension cycle in the FAM-490 channel. Levels of gene expression
were calculated using the comparative ∆∆Ct method, and normalized using gene expression levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), with the iQ5 software (BioRad).
4.9. ELISA Assays
The cell culture media were used for the quantification of TNFα (Peprotech), IL-6 (Peprotech) and
MMP3 (Life Technologies) following the manufacture’s protocols.
4.10. Histological Evaluation
Paraffin-embedded cartilage tissue sections were processed at the Histopathology Department
of Centro Hospitalar e Universitário do Algarve (CHUA, Faro) and used for histological assessment.
Cartilage grading of initial tissue samples was conducted based on modified criteria originally
established by Mankin et al., and the specimens were analyzed for abnormalities in structure,
cellularity and matrix staining, based on hematoxylin-eosin (HE, Bio-Optica, Milano, Italy), safranin-O
(SO)/Fast Green (Sigma-Aldrich, Steinheim, Germany) and toluidine blue (Merck, Darmstadt, Germany)
stainings [56,57]. Four tissue sections from each sample were analyzed.
4.11. Protein Extraction and Quantification
Total protein from chondrocyte inflammatory assays and YP treatments was obtained by extraction
with RIPA buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) for 1 h, at 4 ◦C, with agitation, followed by a centrifugation at 16× g for 15 min at
4 ◦C. Protein concentration was assessed using Micro BCA kit (Thermo Scientific), according to the
manufacturer’s instructions.
4.12. Electrophoresis and Western Blot
Aliquots of 20 µg of total protein extracts were size separated in a 4–12% (w/v) gradient
polyacrylamide precast gel containing 0.1% (w/v) SDS (NuPage, Invitrogen, Carlsbad, CA, USA)
and transferred onto a nitrocellulose membrane (Biorad, Richmond, CA, USA). Detection of pIKBα
and GAPDH was performed through overnight (O/N) incubation with the pIKBα pSer32 ABfinity
Rabbit Monoclonal antibody (2.5 µg/µL, Thermo Fisher, Waltham, MA, USA) and anti-GAPDH
polyclonal antibody (1:500, Santa Cruz Biotechnology). Detection was achieved using Goat
anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody and Western Lightning Plus-ECL
(PerkinElmer Inc., Waltham, MA, USA). Image acquisition was obtained using an IQ LAS 4000 mini
biomolecular imager.
4.13. Determination of Total and Phosphorylated IkBα
Total IkBα and phosphorylated IkBα (pIkBα) were determined in chondrocyte cell lysates, using
the InstantOne ELISA assay kit (Invitrogen) according to the manufacturer’s protocol.
4.14. Statistical Analysis
Each independent experiment (n) was performed with different primary cell culture batches and
cartilage from distinct patients. Replicates within an individual experiment were performed using
the same batch of cells and cartilage from a single patient. Data are presented as mean ± standard
deviation (SD). Multiple t tests were used for comparison between two groups. For more than two
groups significance was determined using one-way analysis of variance (ANOVA) with comparison
between groups by Dunnett test. Statistical significance was defined as p ≤ 0.05 (*), p ≤ 0.005 (**) and
p ≤ 0.0005 (***).
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